Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Bayer is looking to accelerate its patient ... related side effects to be detected much earlier. The German pharmaceutical company has tied up with professional services firm Genpact for the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week. Bayer shareholders call on ...